Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test
For the last several years, an under-the-radar challenger to Big Pharma’s breast cancer franchises has been working on an antibody drug conjugate involving Herceptin. On Tuesday, the Dutch biotech revealed the program had met its primary endpoint in a Phase III study, and they say they’re ready to make a deal.
Byondis’ ADC, combining Herceptin with the experimental drug duocarmazine, reached its goal of a statistically significant improvement of progression-free survival over physician’s choice, the biotech said early Tuesday. None of the data were revealed in the topline results, but Byondis noted it plans to submit its pitch to the FDA by the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.